Abstract: Disclosed is an electrochemiluminescence immunoassay method, using a full reaction of a Ru(bpy) marked protein-primary antibody, a biotinylated protein-secondary antibody to be tested, and a sample to be tested; addition of a Streptavidin-coated magnetic particle to form a complex comprising an antigen, an antibody, and a magnetic particle; adsorption to an electrode surface by the magnetic particle; addition of a dibutyl ethanolamine solution; testing by means of an electrochemical method. Also disclosed is a corresponding electrochemiluminescence immunoassay detection kit.

Abstract: The present invention discloses a service establishment method, device, and system, relating to the field of communications. The method includes: receiving a service indication message, where the service indication message includes service support information about a service initiated by a terminal; and when it is determined on the basis of the service support information that a network format opened by a cell in which the terminal initiates the service does not support the service initiated by the terminal, switching the service initiated by the terminal to a cell that supports the service initiated by the terminal. In the present invention, when a terminal initiates in a cell of an opened network format a service that is not supported by the currently opened network format, the service initiated by the terminal can be established successfully, and the user experience can be improved.

Abstract: The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

Abstract: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein R2 is a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).

Abstract: The present invention provides a novel class of heterocyclic compounds of Formula (I) as modulators of gamma secretase, wherein the definitions of the variables of Formula (I) are defined herein, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

Abstract: A polishing fixture includes a body, two fixing members and a pushing member. The body includes two opposite side walls and a main wall connecting the side walls. Each fixing member is slidably mounted on the corresponding side wall along a first direction. The pushing member is slidably mounted on the main wall along a second direction vertical to the first direction. The pushing member includes pushing pillars resisted against the fixing members. The fixing members are separated from the body to be a smain state when the pushing pillars are pressed into the space enclosed by the body and the fixing members.

Abstract: A touch screen mounting mechanism for mounting a touch screen on a housing includes a base, a mounting board fixed on the base, a push element slidably mounted on the base along the vertical direction of the base, drive members fixed on the mounting board and positioning elements slidably mounted on the surface of the mounting board and located around a positioning slot. The mounting board defines a positioning slot for retaining the touch screen and the housing, the push element defines driving wedge walls, the drive members are used to drive the push element to slide, each positioning element defines a following wedge wall resisting on one driving wedge wall, and in mounting, the following wedge walls are pushed by the driving wedge walls to slide towards the center of the positioning slot to position the touch screen and the housing in the correct order.

Abstract: Embodiments of the present invention relate to a method for establishing a bearer for a machine to machine service and a network transmission device, where the method includes: receiving a user plane resource establishment request message sent by an MTC device, where the user plane resource establishment request message includes at least one of MTC features, QoS requirements, a service indication request and a group identity; determining negotiated QoS parameters according to the user plane resource establishment request message; and establishing a transmission bearer with the MTC device according to the negotiated QoS parameters. The present invention provides a method for establishing a transmission bearer between a network and an MTC device.

Abstract: A method, network element, and mobile station (MS) are disclosed. The method includes: obtaining information that a plug-in card of the MS does not support a first encryption algorithm; deleting the first encryption algorithm from an encryption algorithm list permitted by a core network element according to the information that the plug-in card of the MS does not support the first encryption algorithm; sending the encryption algorithm list excluding the first encryption algorithm to an access network element, so that the access network element selects an encryption algorithm according to the encryption algorithm list excluding the first encryption algorithm and the MS capability information sent from the MS and sends the selected encryption algorithm to the MS. By using the method, network element, and MS, errors due to the fact that the plug-in card of the MS does not support an encryption algorithm may be avoided during the encryption process.

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions.

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of Group A or Group, as defined herein, as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

Abstract: In its many embodiments, the present invention provides novel heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula Compounds of formula (I) include compounds of formulas (IA) and (IB). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula: Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein R2 is a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).